US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations
Executive Summary
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
You may also be interested in...
Valisure Will Continue As 'Inconvenient' Reminder For Change To US Drug Quality ‘Status Quo’
“I think the symptoms of the core disease of quality is not having an independent layer or just not being able to invest more in quality or whatever the other root causes of addressing these quality issues,” says analytical lab president David Light.
US Petition Claims Benzene Forms In Benzoyl Peroxide, Requests Market Removal Of Acne Drugs
Valisure recommends FDA request recall and halt sales of products containing benzoyl peroxide due to its propensity to form the benzene. Products include numerous OTC monograph topical formulations as well Rx drugs with an acne indication available through approved applications.
Mint Flavor Harvest For OTC Famotidine Pioneer Pepcid AC Follows Two ANDA Competitors
Pepcid AC Maximum Strength (20 mg) in Icy Cool Mint tablets available in 20- and 40-count bottles. Walmart’s Equate and Sanofi’s Zantac 360 famotidine formulations already offer mint flavor options.